Form 4: Cytokinetics Officer Exercises Options, Sells Shares

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold a portion of his common stock holdings on March 5, 2026.

Summary

• Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics Inc. (CYTK), reported transactions on March 5, 2026, executed under a Rule 10b5-1 plan.
• Mr. Callos exercised 11,000 non-qualified stock options at an exercise price of $39.13 per share.
• He also exercised an additional 15,000 non-qualified stock options at an exercise price of $23.26 per share.
• Following the option exercises, Mr. Callos sold 15,000 shares of common stock at a price of $61.87 per share.
• An additional 11,000 shares of common stock were sold at a price of $61.88 per share.
• After these reported transactions, Mr. Callos directly beneficially owns 50,440 shares of common stock.
• He also retains beneficial ownership of 24,403 non-qualified stock options with an exercise price of $39.13 and 69,000 non-qualified stock options with an exercise price of $23.26.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction, likely part of a pre-established 10b5-1 plan, which is common for executives managing their equity compensation and personal finances. The exercise of options and subsequent sale of shares does not inherently signal a strong positive or negative outlook for the company.

Positives

• The exercise of stock options indicates the reporting person is realizing value from previously granted equity, which can reflect a positive view of the company's performance at the time the options were granted.
• The transactions were conducted under a Rule 10b5-1 plan, suggesting a pre-arranged and systematic approach to managing equity, which helps mitigate concerns about opportunistic insider trading.

Negatives

• The sale of 26,000 shares of common stock by a key executive could be perceived negatively by some investors, as it reduces their direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as the exercise of stock options and subsequent sale of shares, are common occurrences for executives in publicly traded companies, particularly when managing equity compensation and personal financial planning. The use of a Rule 10b5-1 plan is a standard practice to ensure compliance with insider trading regulations.

Stakeholder Impact

• Shareholders: May view the sale of shares by an executive with slight caution, though the pre-planned nature mitigates concerns. The overall impact is likely minimal given the routine nature of such transactions.
• Employees: No direct impact mentioned.

Key Dates

Keywords

CYTK, Cytokinetics, Form 4, Insider Transaction, Stock Options, Executive Compensation, Andrew Callos, 10b5-1 Plan